Logo

 

 

AUGUST 2022 

Guest editors: Chris Skedgel & Mireia Jofre-Bonet

Alternate text

Remember your sunscreen (and the OHE Prize)!

It’s vacation season here at OHE, as it across most of the Northern hemisphere, so this month’s Bulletin will be brief. We’re going to take the opportunity to encourage you to wear sunscreen at the beach, and maybe while you’re gazing at the waves, to reflect on how can policymakers design a system to generate fair prices that balances access and innovation throughout the lifecycle of medicines?

In the £40,000 OHE Innovation Policy Prize, our judges are looking for innovative solutions to this complex challenge that balance original thinking with feasibility and acceptability, that are based on strong empirical and theoretical foundations, and are explained in clear and compelling terms.

 

Each submission will be judged on the originality of its idea, the strength of its empirical or theoretical foundations, its global feasibility and “implementability”, its potential impact, and the clarity of its explanation. Each criterion will be scored separately, so that "blue sky" ideas that may be farther away from being implementable can be considered on an equal footing to ideas that may be less original but closer to being implementable. In all cases, the judges will be looking for clear and widely accessible explanations of the proposed solution and its potential impacts.

 

OHE is a global thought leader in the economics of innovation, particularly pharmaceutical innovation. We believe that competition and appropriate economic incentives are fundamental to driving innovation but recognise that these must be consistent with ensuring equitable patient access and health system sustainability.

 

In last year’s (virtual) OHE Annual Lecture, Professor Margret Kyle asked whether patents work: evidence from pharmaceutical innovation. She concluded that patents and other forms of Intellectual Property (IP) are effective in incentivising pharmaceutical innovation, but there is more to understand about their efficiency in balancing the benefits of greater innovation against the societal costs of temporarily granting market exclusivities that can restrict access to innovation. Furthermore, she suggested that what may work in one innovative sector may not work in another, making it difficult to apply lessons across sectors. We expect that some submissions to the OHE Prize may suggest alternatives to conventional IP policies, such as “innovation prizes” or more targeted “push” incentives, and we look forward to reading these ideas!

 

With six weeks to go until the deadline, we are sharing a few insights and frequently asked questions around the why, who, how, when – and wish everyone who is working on entries the best of luck. Please do get in touch with us via prizefund@ohe.org if you have any questions which are not covered below.

FREQUENTLY ASKED QUESTIONS

Do you have to be an economist/health economist to enter?

No, we welcome and encourage entries from almost* everyone. We are looking to inspire innovation and out-of-box thinking which does not require economic training. However, and especially in the second round, we are looking for examples of global application of solutions – but our judges will be providing insights and guidance to successful first round applicants.  

 

*The only exemptions are current and past OHE employees/contractors or their families, and current and past OHE board or trustee members. Full terms and conditions can be found here.

 

Do all contributing authors have to be in the UK?

No, we welcome entries from around the world as well as mixed-location entries. The only requirement is that the entries are submitted in the English.

 

Is the OHE Prize free to enter?

Yes.

 

Is there a template for entries?

Yes, the template includes a submission checklist, terms and conditions sign off, and content structure. All submissions will need to be entered in this template.

 

Is there any entry guidance from the judges?

Yes, the judges have identified four key areas for consideration:

  • Incentivising innovation
  • Ensuring access and health system sustainability
  • Signalling social value
  • Global health systems

More information can be found in the authors guidance pack.

 

Does the word limit include references and appendices?

No, these can be submitted at the end of the template and are not included in the solution word limit. The Judges reserve the right not to consider any Appendices attached to the Primary Submissions in devising the shortlist.

 

Are the entries only judged by OHE?

No, we have curated a panel of judges with a vast array of expertise areas. The panel includes three of the OHE leadership team who hold two visiting professors and a honorary research fellow between them plus the Director of Research and the REAL Centre, Chief Executive of the Association of the British Pharmaceutical Industry, Professor at the Department of Health Policy and Management at Columbia University, and Professor of Economics at the Centre d'économie industrielle (Cerna) at Mines ParisTech.

 

Is the judging process impartial?

Yes. Our dedicated Prize Manager will ensure that all entries are anonymous during first and second round judging. The entry origins will only be revealed to the judges after the judging process is completed and the winners are selected.

 

What is the entry process?

In the first round of entries, we are asking for a 500-word summary and 2,500-word solution to our question. Entries must be uploaded to the Prize Portal no later than 23:59:59 on 18 September 2022, late entries will not be accepted.

 

Our judging panel will create a shortlist of the most promising entries who will be invited to write a longer 10,000 solution and a video summary (funded by OHE). Successful entries will also receive feedback notes from our judges on how to elevate their entries. The deadline for submission of second round entries is 23:59:59 27 November 2022.

 

The winner will be announced on the 02 December 2022 and a prize ceremony will be held on 14 December in London where the lead author from the winning paper will be invited to present their solution (reasonable travel expenses paid).


What are the prizes?

All shortlist entries will be published in the new dedicated Prize Hub on ohe.org and have the opportunity to submit a paper to a special issue or section of PharmacoEconomics based on their entry. The runner-up is awarded £10,000 and winning entry is awarded £40,000. The lead author will also be invited, expenses paid, to present their solution at the OHE Innovation Policy Prize ceremony on 14 December 2022 in London.

 

Is the OHE Innovation Policy Prize running annually?

No - it will be running every two years.

MY TOP READ OF THE MONTH

“This will change medicine. It will change research. It will change bioengineering. It will change everything.”

‘It will change everything': DeepMind’s AI makes gigantic leap in solving protein structures  |  July 2022

An artificial intelligence (AI) network invented by Google AI offshoot DeepMind signifies a breakthrough in determining a protein's 3D shape from its amino-acid sequence, one of biology's greatest standing challenges.

 

AlphaFold could mean that less-taxing and easier-to-collect experimental data would 

suffice to get a good understanding of different structures. The evolutionary analysis of proteins is expected to experience a boom due to the huge amount of available genomic data that can now be translated into 3D structures. It is also expected that this breakthrough will transform research in molecular biology, which will gravitate less toward laboratory research and more towards thinking about how to exploit the new information generated by AI networks.

Read

NEW OHE LITERATURE

Alternate text

OHE is leading research to develop an EQ-5D 'bolt-on' for hearing

 

 

OHE, in joint work with the University of Technology Sydney, the University of Oxford, and Maths in Health, have been funded by the EuroQol Research Foundation to develop bolt-on descriptors for hearing.

 

The aim of this project is to fill the development of a  health outcome measurement that is patient-centred. OHE will employ both qualitative and quantitative research methods to develop candidate bolt-ons.

 

Alternate text

Reforming primary health care in middle-income countries: the good, the bad, and the ugly

The depletion or diversion of resources brought about by successive disease outbreaks and geopolitical conflicts pose serious threats to maternal and child health in low- and middle-income countries. 

 

A recent series of papers examines the effects of multiple primary care interventions on maternal and child health under Egypt’s Health Sector Reform Program between 2000 and 2014.

 

This article discusses the main findings and take-home messages useful to understanding the impact of policies in low- and middle-income countries. 

 

Alternate text

Improving the Measurement of Valued Output in Primary Care in England

OHE authors proposed improved measurement of the value of output in primary care in England which reconciles the economic and the health service literatures. OHE has developed a framework and indicators to value primary care output in England. The study shows the importance of choosing a clear perspective, a multi-dimensional framework, and the appropriate output indicators for each  dimension in valuing primary care output,  combining physical output and a value component.

NEWS HIGHLIGHTS

Alternate text

Changes to vocational BTEC health care qualifications could see loss of thousands of new nurse recruits every year | NHS Confederation. 

NHS Employers (part of the NHS Confederation) have raised their concerns to the education secretary that stopping BTEC qualifications in health and social care risks a critical source of health staffing supply.

 

The BTEC scheme has allowed a great number of potential nursing and midwifery recruits to join degree courses yearly. Healthcare leaders across England are warning that stopping these qualifications will compromise an already frail health and social care recruitment sector. This move would compound the perturbances generated by the chronic staff shortages in the NHS labour market ecosystem.

 

Alternate text

Frustration builds in LGBTQ community over government response to monkeypox | CNN

As Monkeypox continues to spread around the world, particularly within the LGBTQ community, people in the US are frustrated by the pace at which vaccines are being provided.

 

According to Sean Cahill, director of health policy research at the Fenway Institute in Boston, “We went from one person diagnosed with monkeypox in mid-May to nearly 5,000 people today. The US government has not done a good job controlling this."

 

Arguably, this slow rollout highlights deficiencies that remain in health systems even after the largely successful COVID-19 vaccination strategies.

Alternate text

U.S. FDA accepts Biogen's ALS therapy for review | Reuters

The US Food and Drug Administration (FDA) has announced that it will re-review the application of tofersen, a first-in-class treatment for amyotrophic lateral sclerosis (also known as motor neuron disease), for its accelerated approval pathway. An initial review in October “did not show a statistically significant improvement in the functional status of patients with fast-progressing ALS.”

 

The resubmission is based on a re-analysis suggesting the drug was effective in slowing progression in patients with a specific gene mutation.

 

This follows a controversial FDA accelerated approval for Aduhelm, a first-in-class treatment for Alzheimer’s disease, based on proxy outcomes and inconclusive evidence of clinical benefit.

 

UPCOMING EVENTS

Alternate text

How to fix the broken antibiotics market? Learnings from pilot 

5 September  |  Virtual 
Antibiotics are the foundation of medicine, but resistance and few new antibiotics pose a significant threat to society. In our upcoming webinar we are inviting experts to discuss why the market for antibiotics is broken and how we can fix it. Focussing on the learnings from the recent NICE-NHS England Antimicrobial Resistance Pilot they will debate the way forward - for the UK and beyond.  

 

Register your free ticket today.

Alternate text

Universal Health Coverage: more than just old wine in a new bottle?

6 October  |  Hybrid

This year, for the first time, the OHE Annual Lecture is hybrid. You now have the opportunity to join us in London at the Royal College of Physicians or virtually from anywhere in the world on the evening of Thursday 6 October for our 2022 lecture 'Universal Health Coverage: more than just old wine in a new bottle?' presented by Eddy van Doorslaer.

 

Alternate text

Our Annual Lecture Series started in 1994 when Sir Douglas Black presented 'A doctor looks at Health Economics'. Throughout the past 28 years we’ve had the privilege of hosting some of the greatest thinkers in the economics of health and health care. The purpose of our Series is to explore urgent and important issues facing health systems around the world and raises awareness of research and evidence that can contribute to addressing these challenges. We hope you can join us, in-person or virtually, for the 2022 instalment.

 

Register your free ticket today.

1. The death toll of Europe’s heat wave – POLITICO

2. Extreme heat is bad for everyone's health -- and it's getting worse - CNN

3. MoMo (isciii.es)

Alternate text

 

Alternate text